CHEK1 and small cell lung carcinoma: A second-generation CHK1 inhibitor, Prexasertib (LY2606368), has been investigated alone or combined with chemotherapy in platinum-sensitive and resistant SCLC models.28 Prexasertib has shown significant single-agent activity in a panel of 39 SCLC cell lines from human and murine, especially in chemotherapy-resistant models.27 Thus, it reinforced the cisplatin effect in both chemotherapy-resistant and -sensitive models, indicating the potential clinical relevance.